Delving into the Latest Updates on SCTT11 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication

Graves Ophthalmopathy

Inactive Indication-

Originator Organization

Shenzhou Cell Engineering Co. Ltd.

Active Organization

Shenzhou Cell Engineering Co. Ltd.

Sinocelltech Group Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Phase Ia: Evaluate the safety and tolerability of a single dose of SCTT11 in healthy subjects and determine the MTD Phase Ib: Evaluate the safety and tolerability of multiple doses of SCTT11 in patients with moderate to severe active TED and determine the MTD; determine the Phase II recommended dose (RP2D) of SCTT11 in patients with moderate to severe active TED

Start Date26 Mar 2025

Sponsor / Collaborator

Shenzhou Cell Engineering Co. Ltd.

NCT06769984

/ Not yet recruitingPhase 1/2

A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Moderate-to-severe Thyroid Eye Disease

Multicentre, Randomized, Double-blinded, Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease

Start Date19 Feb 2025

Sponsor / Collaborator

Sinocelltech Group Ltd.

100 Clinical Results associated with SCTT11

Login to view more data

100 Translational Medicine associated with SCTT11

Login to view more data

100 Patents (Medical) associated with SCTT11

Login to view more data

100 Deals associated with SCTT11

Login to view more data